Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study

Figure 1 Study design. D: Day; BSS: British stool scale; d: day; V: Visit; Y: Yes; N: No; abd: Abdominal; SGA: Subjective global assessment.

Figure 2 Patient selection flow chart. N: Number; V: Visit.

Figure 3 Change in paired abdominal pain scores from baseline to week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3). A: Paired abdominal pain scores; B: Abdominal pain scores (0–10); C: Patient responders (delta > 30%) with respect to abdominal pain. ^cP < 0.001. W: Weeks.

Figure 4 Change in paired bloating scores from baseline to week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3). A: Change in paired bloating scores; B: Abdominal bloating scores (0–10); C: Patient responders (delta > 30%) with respect to bloating. ^cP < 0.001. W: Weeks.

Figure 5 Change in abdominal distension scores from baseline to week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3). A: Change in paired abdominal distension scores; B: Abdominal distension scores (0–10); C: Patient responders (delta > 30%) with respect to abdominal distension. ^cP < 0.001. W: Weeks.

Figure 6 Change in impact of global symptoms on daily life scores from baseline to week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3). A: Paired global symptom scores; B: Global symptom scores (0–10); C: Patient responders (delta > 30%) with respect to global symptoms. ^cP < 0.001. W: Weeks.

Figure 7 Changes in stool from baseline to week 4 of GASTRAP^® DIRECT treatment (visit 1 to visit 3). A: Restoration of stool consistency {hard stool [Bristol stool scale (BSS) score 1–2] to normal; liquid stool (BSS 6–7) to normal}; B: Relief of altered stool pattern.

Figure 8  Tolerability of GASTRAP^® DIRECT evaluated at week 4.